Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  EntreMed Inc       US29382F2020

SummaryNewsCalendarCompany 
Business Summary
Develops pharmaceutical drugs for treating cancer & inflammatory diseases

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs with commercial focus on the China market.

The Company operates through one business segment, which is the development of targeted therapeutics primarily for the treatment of cancer.

The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau.

The drugs are Captisol-Enabled, ZEVALIN and MARQIBO.

CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, MD.

Number of employees : 22 persons.
Sales per Businesses
20132014Delta
USD (in Million)%USD (in Million)%
Therapeutics--0.024100%-
Sales per Regions
20132014Delta
USD (in Million)%USD (in Million)%
United States and China--0.024100%-
Managers
NameAgeSinceTitle
Ken Keyong Ren MD, PhD562012Chief Executive Officer & Director
Wei-Wu He PhD, MBA502012Executive Chairman
Cynthia Wong Hu452006COO, Secretary, Vice President & General Counsel
Sara B. Capitelli, CPA482011Chief Accounting Officer & Vice President-Finance
Rong Chen MD, PhD-2015Chief Medical Officer
Tak W. Mak, PhD682012Director
James Z. Huang, MBA492013Independent Director
Yue Alexander Wu PhD, MBA512013Independent Director
Franklin Cary Salisbury, Jr.592014Independence Director
Rajesh C. Shrotriya, MD712014Independent Director
Shareholders
NameShares%
IDG Capital Partners Co., Ltd. 6,842,783 21.1%
Spectrum Pharmaceuticals, Inc. 5,405,382 16.7%
Sabby Capital LLC 836,092 2.58%
Wellington Shields Capital Management LLC 571,695 1.76%
Wellington Shields & Co. LLC 504,861 1.56%
Emerging Technology Partners LLC 441,072 1.36%
Kleiner Perkins Caufield & Byers LLC 416,666 1.28%
The Vanguard Group, Inc. 400,060 1.23%
Tak W. Mak, PhD 365,376 1.13%
BlackRock Fund Advisors 257,866 0.79%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Biotechnology & Medical Research - NEC
Advertisement
Sector Biotechnology & Medical Research
Growth (Revenue) Profitability
PHARMACYCLICS, IN..
INCYTE CORPORATIO..
ALNYLAM PHARMACEU..
CELLTRION, INC.
ALKERMES PLC
QUINTILES TRANSNA..
UNITED THERAPEUTI..
ISIS PHARMACEUTIC..
PUMA BIOTECHNOLOG..
-
QIAGEN NV
INTREXON CORP
SEATTLE GENETICS,..
ICON PLC
BIO-TECHNE CORP
ACADIA PHARMACEUT..
SYNAGEVA BIOPHARM..
PAREXEL INTERNATI..
BB BIOTECH AG
CHARLES RIVER LAB..
WUXI PHARMATECH (..
Sector Biotechnology & Medical Research
EntreMed Inc : Connections
National Academy of Sciences
ImmunoVentis, Inc.
Cytomyx Holdings Plc
University of Toronto
Crown Bioscience, Inc.
OriGene Technologies, Inc.
Intradigm Corp.
The Campbell Family Institute for Breast Cancer Research
Amnis Corp.
American Academy of Arts & Sciences
MithraGen, Inc.
Wuhan Kindstar Diagnostics Co., Ltd.
Emerging Technology Partners LLC
National Foundation for Cancer Research
Miikana Therapeutics, Inc.
Allos Therapeutics, Inc.
Company contact information
CASI Pharmaceuticals, Inc.
9620 Medical Center Drive
Suite 300
Rockville, MD 20850

Phone : +1.240.864.2600
Fax : +1.240.315.2437
Web : www.casipharmaceuticals.com
© 2015 People , Fundamentals and Ownership   
Dynamic quotes  
ON
| OFF